How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,796 results for

Aspartate Aminotransferase

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

aminotransferase (19% versus 39%), conjunctivitis (19% versus 4.0%), nausea (19% versus 22%) and increased aspartate aminotransferase (19% versus 36%). The most frequently reported serious adverse events in the dacomitinib and gefitinib groups respectively were: disease progression (3.5% versus 4.9%), diarrhoea (2.2% versus 0%), pleural effusion (2.2% versus 0.9%), pneumonia (2.2% versus 0.9%) and dyspnoea (0.4% versus 1.8%). 2 Three deaths were considered to be related to study treatment toxicity. Two

2019 Scottish Medicines Consortium

282. Management of Rheumatod Arthritis

) • changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (HR=0.14, 95% CI 0.04 to 0.48) However, it has significantly more renovascular AEs (oedema and hypertension). There is no difference in cardiac AEs and renal dysfunction. 31-32, level I Celecoxib 200 mg daily is as safe as placebo in the incidence of gastroduodenal ulcers =3 mm but safer compared with traditional NSAIDs (NNH=9, 95% CI 8 to 10). There is no conclusive evidence that celecoxib has more CV events than

2019 Ministry of Health, Malaysia

283. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations. Full Text available with Trip Pro

) (22) . ALT = alanine aminotransferase; AST = aspartate aminotransferase; BP = blood pressure; Cr = creatinine; mo = months; NSAID = nonsteroidal antiinflammatory drug; ULN = upper limits of normal; VKA = vitamin K antagonist; y = years. Assessment of Patient Thromboembolic Risk Patients who have had a stroke or venous thromboembolic event or have an underlying malignancy or a significant cardiovascular disease history are particularly prone to thrombotic events ( Table 1 ) ( x 8 Kearon, C., Akl

2019 Society of Interventional Radiology

284. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation

Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation Alanine aminotransferase (ALT) and aspartate aminotransferase (...) , have been reported in patients treated with tocilizumab; some cases required liver transplantation advise patients to seek medical help immediately if they experience signs and symptoms of liver injury, such as tiredness, abdominal pain, and jaundice monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at initiation, every 4–8 weeks during the first 6 months of treatment, and every 12 weeks thereafter in patients with rheumatological indications exercise caution when

2019 MHRA Drug Safety Update

286. Diagnosis and Management of Glycogen Stored Diseases type VI and IX a practice resource of ACMG

-hydroxybutyrate (ß-OHB) levels increase only modestly in GSD I 22,55 as it is considered a hypoketotic hypoglycemic state. In contrast, hyperketonemia with fasting hypoglycemia is more common in GSDs III, VI, and IX. 22 Hepatic transaminase levels (aspartate aminotrans- ferase [AST] and alanine aminotransferase [ALT]) are significantly higher in GSD III, VI, and IX as compared with GSD I.InGSD IAST andALT are usuallymodestlyincreased to ~100U/L in the early stages of the disease with a tendency to normalize (...) of fasting hypoglycemia, significant splenomegaly; storage cells characteristic of the disease, other features like bone and pulmonary involvement ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, GSD glycogen storage disease, PT prothrombin time. ACMG PRACTICE RESOURCE KISHNANI et al 6 Volume 0 | Number 0 | Month | GENETICS in MEDICINEhypoglycemia is indicated to rule out endocrine causes, particularly when hepatomegaly is not a significant feature. A more detailed workup

2019 American College of Medical Genetics and Genomics

289. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

of statins. A genome-wide association study in participants from the SEARCH RCT evaluated 85 subjects who had developed definite myopathy (defined as muscle symptoms with CK >10 times the ULN) or “incipient myopathy” (defined as CK >3 times ULN and >5 times baseline levels, plus alanine aminotransferase [ALT] >1.7 times baseline levels without an elevated ALT alone at any other visit, with or without muscle symptoms) on simvastatin 80 mg and compared them with 90 participants who were also allocated

2019 American Gastroenterological Association Institute

290. Practice Advisory: Hepatitis B Prevention

liver disease include, but are not limited to, those with hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase or aspartate aminotransferase level greater than twice the upper limit of normal. This Practice Advisory was developed by the American College of Obstetricians and Gynecologists’ Immunization and Emerging Infections Expert Work Group in collaboration with Brenna L. Hughes, MD. References 1. Schillie S

2019 American College of Obstetricians and Gynecologists

293. Nivolumab (melanoma) - Addendum to Commission A16-35

) Musculoskeletal and connective tissue disorders 96 (45.3) 94 (43.7) Arthralgia 39 (18.4) 33 (15.3) Back pain 20 (9.4) 28 (13.0) Respiratory, thoracic and mediastinal disorders 99 (46.7) 88 (40.9) Cough 44 (20.8) 42 (19.5) Dyspnoea 44 (20.8) 32 (14.9) Infections and infestations 98 (46.2) 83 (38.6) Nervous system disorders 89 (42.0) 88 (40.9) Headache 44 (20.8) 40 (18.6) Dizziness 23 (10.8) 18 (8.4) Investigations 106 (50.0) 69 (32.1) Alanine aminotransferase increased 40 (18.9) 12 (5.6) Aspartate (...) (9.4) 20 (9.3) Colitis 18 (8.5) 19 (8.8) General disorders and administration site conditions 23 (10.8) 13 (6.0) Fatigue 12 (5.7) 3 (1.4) Skin and subcutaneous tissue disorders 16 (7.5) 6 (2.8) Respiratory, thoracic and mediastinal disorders 19 (9.0) 6 (2.8) Infections and infestations 21 (9.9) 17 (7.9) Nervous system disorders 12 (5.7) 11 (5.1) Investigations 62 (29.2) 26 (12.1) Alanine aminotransferase increased 19 (9.0) 6 (2.8) Aspartate aminotransferase increased 16 (7.5) 4 (1.9) Lipase

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

297. Scleroderma Morphea

localized scleroderma/morphea “en coup de sabre” • Progressive facial hemiatrophy (Parry–Romberg syndrome) Deep type • Deep morphea a Mixed type b Eosinophilic fasciitis (Shulman syndrome) c 26 Table 2 Laboratory parameters in localized scleroderma LS, localized scleroderma. Blood differential • Important in linear types of LS and in eosinophilic fasciitis because of eosinophilia Clinical chemistry • Transaminases (aspartate aminotransferase and alanine transaminase) – elevated transamninases are seen

2018 European Dermatology Forum

300. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis Full Text available with Trip Pro

on a large scale. For patients prior to treatment with a biologic Pre-treatment investigations Baseline assessment for all should include (grade 1C SOA 98%): laboratory evaluation of full blood count (FBC), creatinine/calculated glomerular filtration rate (GFR), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), albumin, tuberculin skin test (TST) or interferon-gamma release assay (IGRA) or both as appropriate, hepatitis B and C serology, and a chest radiograph. Baseline assessment

2018 British Society for Rheumatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>